Navigation Links
Drug for Deadly Lung Disease Shows Promise

Idiopathic pulmonary fibrosis kills 40,000 Americans each year

FRIDAY, May 23 (HealthDay News) -- Patients with a progressive fibrosis of the lungs that's fatal within a few years of diagnosis may finally have some reason for hope.

Japanese researchers say daily use of the drug pirfenidone improved the lung function and lengthened the survival of patients with the illness, called idiopathic pulmonary fibrosis (IPF).

"Patients look to any research in IPF with a sense of hope, because right now, there's very little that can be done for them," said Mark Shreve, founder and chief operating officer of the Coalition for Pulmonary Fibrosis, based in San Jose, Calif.

"To say that there's a desperate need -- even that would be an incredible understatement, because you are talking about a devastating, relentless disease that has a survival rate of less than three years, and no proven cause and no treatment," he said.

But the results of the new phase III clinical trial, involving 275 Japanese patients with mild-to-moderate IPF, may change all that. The findings were presented this week at the annual meeting of the American Thoracic Society, in Toronto.

According to Shreve, 128,000 Americans are battling IPF at any given time. Each year, 48,000 new cases are diagnosed, and 40,000 people die from the illness -- equal to the annual death toll from breast cancer.

IPF's origins remain largely unknown. It typically arises in late middle-age or the senior years and involves a progressive fibrosis: a process in which healthy lung tissue turns into useless scar tissue. This hardening of the lungs gradually and relentlessly robs patients of their ability to breathe.

"There's no drug, period, that's ever been approved for IPF," Shreve said. "Right now, the only treatment option that's been shown to extend the lives of patients is a lung transplant. But, other than that, the disease itself is an incredibly progressive, severe relentless disease."

That's why the results of the new trial have generated a level of cautious excitement among the IPF research community. In the study, a team led by Dr. Takashi Ogura, of Kanagawa Cardiovascular and Respiratory Center, Yokohama, gave patients either high-dose (1,800 milligrams) or low-dose (1,200 milligrams) pirfenidone or a placebo each day. Then they tracked changes in lung capacity, disease progression and patient survival over the course of a year.

Ogura's team reported that patients on high-dose pirfenidone achieved significantly less deterioration in lung capacity compared to those not on the drug. Those placed on the medication also displayed a slowdown in disease progression. Side effects included skin rash and loss of appetite.

"Taken together, our study demonstrated positive clinical effects of pirfenidone that suppresses the progress of IPF and potentially contributes to improving the outcomes of patients with IPF," Ogura said in a prepared statement.

Pirfenidone is "a drug in its own class," explained Dr. Ganesh Raghu, director of the Interstitial Lung Disease/Sarcoid/Pulmonary Fibrosis Program at the University of Washington Medical Center, in Seattle. His team pioneered the use of pirfenidone -- which is thought to have anti-inflammatory and anti-fibrotic properties -- against IPF more than a decade ago.

"It has taken this long -- 11, 12 years -- for it to reach the stage of phase III. I'm quite pleased that a drug of potential efficacy or anti-fibrotic effect is used for IPF. The Japanese trial is encouraging," said Raghu, who is also professor of pulmonary and critical care medicine at the University of Washington.

Still, he stressed that the population used in the Japanese trial may not represent the full spectrum of IPF patients, so it's too early to tell if pirfenidone will work for everyone with the disease. A larger, multi-center trial using the drug is currently under way in Europe and North America, with results expected later this year.

"Until further studies that enroll large number of patients and include all spectrum of patients with IPF, we cannot extrapolate the findings to the entire patient population with IPF," Raghu said.

He also cautioned that pirfenidone has not yet been approved for use against any medical condition by the U.S. Food and Drug Administration, meaning that IPF patients can only get the medicine by participating in a clinical trial.

And while pirfenidone may slow the progression of IPF, it does not stop it, Shreve noted.

"If this drug works out, that's fantastic, but it's still not a cure," Shreve said. "With a cure -- that's when we'll be really excited."

More information

To learn more about IPF, visit the Coalition for Pulmonary Fibrosis.

SOURCES: Mark Shreve, founder and chief operating officer, Coalition for Pulmonary Fibrosis, San Jose, Calif; Ganesh Raghu, M.D., professor, medicine and laboratory medicine, pulmonary and critical care medicine, and director, Interstitial Lung Disease/Sarcoid/Pulmonary Fibrosis Program, University of Washington Medical Center, Seattle; May 20, 2008, presentation, American Thoracic Society's annual meeting, Toronto

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. World Vision Appealing for $2 Million for Deadly China Quake
2. Melanomas on Scalp and Neck More Deadly
3. Study sheds light on deadly lung disease
4. Infection Experts Report Reveals the CDCS Deadly Mistakes
5. Stopping a deadly killer
6. Deadly disease eliminated in children under 5 years of age in Uganda
7. Mother-daughter conflict, low serotonin level may be deadly combination
8. Researchers find possible target to treat deadly bloodstream infections
9. Heart Attacks in Hospital More Deadly at Night, on Weekends
10. Choking Game Turned Deadly for 82 Youths
11. Mutual Resentment in Marriage Can Be Deadly
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: